RVVTF...387...Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application TORONTO, March 19, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (?Revive? or the ?Company?) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce positive results of a pre-clinical study evaluating the efficacy of psilocybin in the treatment of mild traumatic brain injury (?TBI?) in a rodent model of TBI. The study was conducted at the National Health Research Institutes (?NHRI?), which was part of the psilocybin program acquired from PharmaTher Inc., a subsidiary of Newscope Capital Corporation (CSE: PHRM, OTCQB: PHRRF)...
|